Company Overview
PolyPid Ltd. operates as a biopharmaceutical entity dedicated to developing targeted, locally administered, and prolonged-release therapeutics designed to address unmet medical needs through its proprietary polymer-lipid encapsulation matrix (PLEX) technology. The company functions within the healthcare sector, specifically the biotechnology industry, which implies a focus on innovative drug discovery and development rather than established manufacturing or distribution. PolyPid maintains a market capitalization of $81.68M and employs 69 individuals, reflecting a small-cap structure typical of early-stage biotechnology firms. The combination of an $81.68M market cap and N/A annual revenue indicates that the company's valuation is driven primarily by potential future product pipelines and intellectual property rather than current commercial earnings.
Financial Health
The company reported N/A for revenue (TTM) alongside a net income (TTM) of $-34,169,000 and an EBITDA of $-31,509,000, revealing a cost structure where operational expenses significantly exceed any generated revenue. The absence of reported revenue alongside substantial losses highlights the heavy investment required in research and development before a product candidate achieves commercial viability. PolyPid generated free cash flow of $-15,795,625, indicating that the company is burning cash to fund its operations and technology development rather than generating liquidity from business activities. All three margin metrics—gross margin at 0.0%, operating margin at 0.0%, and profit margin at 0.0%—reflect the company's pre-revenue status where no sales have yet occurred to generate gross or operating profits. The balance sheet holds $12.93M in cash against $2.80M in debt, resulting in a debt-to-equity ratio of 25.48, which suggests the company is leveraging its capital but remains primarily cash-funded to sustain operations. The current ratio stands at 1.97, indicating that the company possesses sufficient liquid assets to cover its short-term liabilities nearly twice over. Return on Equity is -366.3% and Return on Assets is -86.7%, metrics that reveal management is utilizing shareholder and asset bases to generate negative returns due to significant losses relative to the company's equity and asset base.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is -4.63, implying that analysts or market models project continued negative earnings or a specific normalization of losses in the near future. The price-to-book ratio is 7.10, suggesting that the market values the company's equity at a significant premium over its accounting book value, likely reflecting the high perceived potential of its PLEX technology. The price-to-sales ratio is N/A because there is no sales revenue, and the EV/EBITDA stands at -2.27, which serves as an alternative valuation metric indicating the company is trading at a negative multiple due to its negative earnings before interest, taxes, depreciation, and amortization. PolyPid has traded between a 52-week high of $5.12 and a 52-week low of $2.30, with the current price position relative to this range dependent on the specific trading day but historically bounded by these extremes. The beta of 1.55 indicates that the stock exhibits high volatility, moving 55% more than the broader market, which is characteristic of small-cap biotechnology stocks with limited liquidity and high risk.
Growth & Income
Revenue growth (YoY) is N/A and earnings growth (YoY) is N/A, as the company has not yet generated positive revenue to establish a growth trajectory. Since earnings are negative and revenue is N/A, it is impossible to determine if earnings are growing faster or slower than revenue, but the implication is that the company is in a phase of development rather than commercial expansion. As a non-dividend payer, PolyPid has a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources, including its $12.93M cash reserves, into research and development rather than distributing income to shareholders. The overall growth and income profile for PolyPid is characterized by a lack of current commercial earnings and dividend income, focusing entirely on the development of its lead product candidate, D-PLEX100, to eventually achieve profitability.